Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb announce Orencia success

Bristol-Myers Squibb announce Orencia success

10th April 2008

Bristol-Myers Squibb (BMS) has announced that a new drug which aims to reduce signs and symptoms of polyarticular juvenile idiopathic arthritis (JIA) has been a success.

It is reported that the manufacturer’s Orencia treatment, which targets paediatric patients over the age of six who display moderate or severely symptoms of JIA, has been approved by the US Food and Drug Administration.

The company claims Orencia can be used as a monotherapy or alongside methotrexate and has been proven safe and effective as part of a recent three-part study which took place over one year.

Dr Edward Giannini professor of paediatrics in the rheumatology division of Cincinnati Children’s Hospital Medical Centre welcomed the success of the treatment.

“In a JIA clinical trial, Orencia provided meaningful and sustained improvements in this patient population across three major sub-types of JIA through one year,” he said.

BMS was recently honoured by the Green Building Initiative for the environmental improvement of some of its existing facilities, myrecordjournal.com reports.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.